Pharmacyte Biotech Stock Performance
| PMCB Stock | USD 0.72 0.01 1.44% |
The company holds a Beta of 3.21, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, PharmaCyte Biotech will likely underperform. At this point, PharmaCyte Biotech has a negative expected return of -0.12%. Please make sure to check PharmaCyte Biotech's potential upside, day median price, and the relationship between the treynor ratio and accumulation distribution , to decide if PharmaCyte Biotech performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days PharmaCyte Biotech has generated negative risk-adjusted returns adding no value to investors with long positions. Despite latest weak performance, the Stock's fundamental indicators remain strong and the current disturbance on Wall Street may also be a sign of long term gains for the company investors. ...more
Last Split Factor 1:1550 | Last Split Date 2021-07-12 |
1 | Disposition of tradable shares by Liquard Thomas of PharmaCyte Biotech subject to Rule 16b-3 | 10/15/2025 |
2 | Will PharmaCyte Biotech Inc. stock reach all time highs in 2025 - July 2025 Earnings Consistent Growth Equity Picks - newser.com | 10/29/2025 |
3 | What Fibonacci levels say about PharmaCyte Biotech Inc. rebound - Weekly Trade Summary Growth Oriented Trading Recommendations - newser.com | 11/04/2025 |
4 | Form 4 PharmaCyte Biotech, Inc. Insider Trading Activity - Stock Titan | 11/18/2025 |
5 | PharmaCyte Biotech Inc. Stock Price Live Quotes Charts NASDAQ - StocksToTrade | 12/04/2025 |
6 | PharmaCyte Biotech faces NASDAQ non-compliance notice - MSN | 12/09/2025 |
7 | Disposition of 16875 shares by Abecassis Michael M of PharmaCyte Biotech at 1.02 subject to Rule 16b-3 | 12/12/2025 |
8 | Nuvilex Issues Earnings Results | 12/18/2025 |
| Begin Period Cash Flow | 50.2 M | |
| Total Cashflows From Investing Activities | -7 M |
PharmaCyte | Build AI portfolio with PharmaCyte Stock |
PharmaCyte Biotech Relative Risk vs. Return Landscape
If you would invest 97.00 in PharmaCyte Biotech on September 30, 2025 and sell it today you would lose (24.98) from holding PharmaCyte Biotech or give up 25.75% of portfolio value over 90 days. PharmaCyte Biotech is currently does not generate positive expected returns and assumes 9.2854% risk (volatility on return distribution) over the 90 days horizon. In different words, 83% of stocks are less volatile than PharmaCyte, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
PharmaCyte Biotech Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for PharmaCyte Biotech's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as PharmaCyte Biotech, and traders can use it to determine the average amount a PharmaCyte Biotech's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0128
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | PMCB |
Based on monthly moving average PharmaCyte Biotech is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of PharmaCyte Biotech by adding PharmaCyte Biotech to a well-diversified portfolio.
PharmaCyte Biotech Fundamentals Growth
PharmaCyte Stock prices reflect investors' perceptions of the future prospects and financial health of PharmaCyte Biotech, and PharmaCyte Biotech fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on PharmaCyte Stock performance.
| Return On Equity | -0.18 | ||||
| Return On Asset | -0.0476 | ||||
| Current Valuation | (7.51 M) | ||||
| Shares Outstanding | 10.13 M | ||||
| Price To Earning | 9.57 X | ||||
| Price To Book | 0.20 X | ||||
| EBITDA | 30.66 M | ||||
| Net Income | 30.66 M | ||||
| Cash And Equivalents | 82.23 M | ||||
| Cash Per Share | 3.96 X | ||||
| Total Debt | 3.28 M | ||||
| Current Ratio | 75.51 X | ||||
| Book Value Per Share | 5.25 X | ||||
| Cash Flow From Operations | (2.98 M) | ||||
| Earnings Per Share | (1.11) X | ||||
| Market Capitalization | 7.2 M | ||||
| Total Asset | 55.17 M | ||||
| Retained Earnings | (84.97 M) | ||||
| Working Capital | 19.46 M | ||||
| Current Asset | 1.6 M | ||||
| Current Liabilities | 449 K | ||||
About PharmaCyte Biotech Performance
By analyzing PharmaCyte Biotech's fundamental ratios, stakeholders can gain valuable insights into PharmaCyte Biotech's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if PharmaCyte Biotech has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if PharmaCyte Biotech has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 148.25 | 140.84 | |
| Return On Tangible Assets | 0.57 | 0.60 | |
| Return On Capital Employed | (0.08) | (0.09) | |
| Return On Assets | 0.56 | 0.58 | |
| Return On Equity | 0.59 | 1.06 |
Things to note about PharmaCyte Biotech performance evaluation
Checking the ongoing alerts about PharmaCyte Biotech for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for PharmaCyte Biotech help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| PharmaCyte Biotech generated a negative expected return over the last 90 days | |
| PharmaCyte Biotech has high historical volatility and very poor performance | |
| PharmaCyte Biotech has some characteristics of a very speculative penny stock | |
| PharmaCyte Biotech currently holds about 82.23 M in cash with (2.98 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.96, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| PharmaCyte Biotech has a poor financial position based on the latest SEC disclosures | |
| Latest headline from thelincolnianonline.com: Nuvilex Issues Earnings Results |
- Analyzing PharmaCyte Biotech's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether PharmaCyte Biotech's stock is overvalued or undervalued compared to its peers.
- Examining PharmaCyte Biotech's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating PharmaCyte Biotech's management team can have a significant impact on its success or failure. Reviewing the track record and experience of PharmaCyte Biotech's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of PharmaCyte Biotech's stock. These opinions can provide insight into PharmaCyte Biotech's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for PharmaCyte Stock analysis
When running PharmaCyte Biotech's price analysis, check to measure PharmaCyte Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PharmaCyte Biotech is operating at the current time. Most of PharmaCyte Biotech's value examination focuses on studying past and present price action to predict the probability of PharmaCyte Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PharmaCyte Biotech's price. Additionally, you may evaluate how the addition of PharmaCyte Biotech to your portfolios can decrease your overall portfolio volatility.
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets |